Evotec, NetraMark, Novo Nordisk – From the lab to a golden digital future with artificial intelligence

Evotec - AI drives innovation in drug discovery

Evotec is increasingly relying on artificial intelligence (AI) to expand its position in drug development. One building block is the partnership with the French AI specialist Owkin, which has been running since the beginning of 2024. Together, they identify targets for therapies in oncology and immunology – supported by Evotec's platform for validation and drug optimization. In addition, the Company is integrating AI into antimicrobial research, combined with high-throughput screening. In the long term, Evotec aims to play a leading role in precision medicine, using AI-based algorithms from target discovery to drug optimization.

On March 4, 2025, Evotec announced a milestone in its collaboration with Bristol Myers Squibb. A research payment of USD 20 million was made for a preclinical neurodegeneration program. The partnership, which has been in place since 2016, aims to develop therapies that slow down the progression of disease – a market with high unmet medical needs. Despite the progress, the stock market reacted negatively and plummeted, breaking through the 200-day line. Analysts suspect that uncertainties about the upcoming publication of the annual report on April 17 and the forthcoming CFO change are depressing sentiment.

Evotec's management remains in a state of flux. Following the surprise resignation of CFO Laetitia Rouxel at the end of February, Paul Hitchin, former CFO of Mediq, is taking over the role. Hitchin is expected to push ahead with the cost-cutting strategy after the Company reported a 5.8% decline in revenue in the most recent quarter. It is also assumed that a loss will be reported for the past year. Investors are now pinning their hopes on the planned efficiency measures and the long-term focus on profitable growth – a balancing act between short-term risks and long-term potential. The share is currently available for EUR 6.55.

NetraMark - How AI is redefining clinical trials

NetraMark's focus is NetraAI – a generative AI platform designed specifically for clinical trial analysis. In contrast to conventional machine learning models, which often fail due to small data sets, NetraAI identifies "explainable" patient subgroups. This technology filters out confounding factors and isolates variables that allow hypotheses to be derived to select an appropriate patient group for Phase 3 studies. Recent results presented by the Company at the ISCTM conference show that the platform significantly improved prediction accuracy in depression by 28% and reduced misclassification in schizophrenia studies.

NetraMark is collaborating with the Ontario Brain Institute (OBI) to use AI to optimize brain data analysis in depression. The goal is to develop a pipeline that fuses MRI, fMRI, and MEG data with clinical information. Graph theory will be used to identify novel biomarkers that model brain network dynamics. The open-access platform is designed to make studies more efficient and enable personalized treatment approaches. The partnership underscores NetraMark's strategic positioning in the growth area of neuropsychiatric disorders. If the AI-based tools can be shown to make Phase 3 studies more cost-effective, this could accelerate their use in other indications.

NetraMark has raised over CAD 3 million since December 2024 by exercising warrants and options to expand its AI solution, NetraAI. Management is well-positioned for the next steps. CEO George Akelios, a former IBM employee, is driving commercialization, while CTO Dr. Joseph Geraci, a pioneer in mathematical AI models, is shaping the scientific roadmap. This duality of market pragmatism and depth of research positions NetraMark as a bridge builder between innovative technology and regulatory requirements. This is a distinct advantage in the complex environment of clinical trials. The share price has risen by 76% since the beginning of the year and is currently trading at CAD 1.44.

Novo Nordisk - AI as an innovation driver

For Novo Nordisk, AI is a key technology used in its research and production processes. Through strategic alliances with partners such as Microsoft, Valo Health, and MIT, the Company is expanding its AI capabilities in a targeted manner. One focus is on drug discovery. Using Valo's Opal platform, Novo Nordisk is identifying candidates for treatments for diabetes, obesity, and cardiovascular diseases. At the same time, AI is optimizing production processes – from deep learning in quality control to the automation of regulatory documents. Algorithms developed in collaboration with Microsoft also improve risk prediction in heart patients by 8%. In the long term, the Company is relying on quantum computing and generative AI to further accelerate drug development.

Novo Nordisk closed 2024 with a 26% increase in revenue to DKK 290.4 billion, driven by diabetes and obesity treatments. The Obesity Care division grew by 57%, while the acquisition of Catalent production facilities should stabilize supply chains. Despite these successes, challenges lie ahead. The Phase III study of CagriSema, for example, showed a weight reduction of 15.7% but fell short of expectations. This raises doubts about whether Novo Nordisk can maintain its market leadership against Eli Lilly's Mounjaro. In addition, analyst forecasts point to slower growth through 2027. For 2025, the Company expects revenue growth of up to 24% – assuming new therapies such as the hemophilia-effective Mim8 receive timely approvals.

Novo Nordisk's shares have lost over 50% of their value from their peak in June 2024 due to disappointing study data and concerns about competitiveness. However, the current valuation offers opportunities. The price-to-earnings ratio of 18.9 is below 20 again for the first time in a long time, and the price-to-earnings-growth ratio is below 1, signaling an undervaluation. Although uncertainties due to delays at CagriSema and supply bottlenecks are weighing on sentiment, structural advantages such as scaled production and high customer loyalty suggest resilience. The stock is currently available for EUR 69.38.

The pharmaceutical industry is being redefined by AI. Evotec is driving drug discovery with partnerships such as Owkin and Bristol Myers Squibb but is struggling with falling share prices and management upheaval. NetraMark is revolutionizing clinical trial analysis with NetraAI, as demonstrated by its success in psychiatric disorders. Novo Nordisk uses AI alliances for diabetes and obesity therapies. Despite disappointing study data and a drop in share price, growth remains robust. AI can pave the way to precision medicine, thus providing companies with a leading role in the multi-billion-dollar healthcare market.